SPOTLIGHT: Drug scandals cause second-guessing

Recent drug news--from Zyprexa's weight gain-and-diabetes problem to Avandia's heart attack warning to the recent hoopla over Vytorin--have some people asking whether drug therapy is all it's cracked up to be. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.